Cancer survivors in the united states: A review of the literature and a call to action

International Journal of Medical Sciences

Volumn 9, Issue 2, 2012, Pages 163-173

  Valdivieso, Manuel ^a,b   Kujawa, Ann M ^b   Jones, Tisha ^b   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ProMedica Cancer Institute   (United States)

Author keywords

Cancer survivorship; Detection of treatment complications; Secondary malignancies; Side effects of therapy; Socioeconomic legal healthcare policy issues

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MITOMYCIN C; PACLITAXEL;

BEHAVIOR THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CHILDHOOD CANCER; CHRONIC DISEASE; CLINICAL RESEARCH; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; EMPLOYMENT DISCRIMINATION; HEALTH INSURANCE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN RIGHTS; INFECTION COMPLICATION; JOINT PROSTHESIS; LEGAL ASPECT; LUNG DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; ONSET AGE; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT MONITORING; PHYSICAL DISEASE; QUALITY OF LIFE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION SAFETY; REVIEW; SECOND CANCER; SEXUAL DYSFUNCTION; SIDE EFFECT; UNEMPLOYMENT; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; COUNSELING; HEALTH BEHAVIOR; HEART; HUMANS; INCIDENCE; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; QUALITY OF LIFE; SURVIVORS; UNITED STATES;

EID: 84856773049     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.3827     Document Type: Review

References (78)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society. 2010.
2. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27(17):2758-2765.
3. Heron M. Deaths: Leading causes for 2006; National vital statistics reports Vol 58. Hyattsville, MD: National Center for Health Statistics; 2010.
4. [Internet] Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007; based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://seer.cancer.gov/csr/1975_2007/
5. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009;18(4):1033-1040.
6. Centers for Disease Control and Prevention (CDC). Cancer survivorship--United States, 1971-2001. MMWR Morb Mortal Wkly Rep 2004;53(24):526-529.
7. Coleman MP, Forman D, Bryant H, et al. and the ICBP Module 1 Working Group. Lancet 2011; 377 (9760): 127-138.
8. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004;54(4):208-236.
9. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355(15):1572-1582.
10. Mulhern RK, Palmer SL. Neurocognitive late effects in pediatric cancer. Curr Probl Cancer 2003;27(4):177-197.
11. Langeveld NE, Stam H, Grootenhuis MA, et al. Quality of life in young adult survivors of childhood cancer. Support Care Cancer 2002;10(8):579-600.
12. Haupt R, Fears TR, Robison LL, et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA 1994;272(18):1427-1432.
13. Wiener L, Battles H, Bernstein D, et al. Persistent Psychological Distress in Long-Term Surviviors of Pediatric Sarcoma: The Experience at a Single Institution. Psychooncology, 2006; 15 (10): 898-910.
14. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25(25):3991-4008.
15. Valdivieso M, Kraut M, Lattin P, et al. Pulmonary functions tests predict for pulmonary toxicity in non-small cell lung cancer patients receiving chemotherapy and radiotherapy. Proc AACR. 1992; 33:226.
16. Brooks BJ, Jr., Seifter EJ, Walsh TE, et al. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. J Clin Oncol 1986;4(2):200-209.
17. Theuws JC, Muller SH, Seppenwoolde Y, et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. J Clin Oncol 1999;17(10):3091-3100.
18. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270(16):1949-1955.
19. Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000;48(1):169-179.
20. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995;1(1):33-42.
21. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332(26):1738-1743.
22. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004;91(1):37-44.
23. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14(1):14-24.
24. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant 2005;24(12):2196-2201.
25. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710-717.
26. Minotti G, Licata S, Saponiero A, et al. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem Res Toxicol 2000;13(12):1336-1341.
27. Ryberg M, Nielsen D, Skovsgaard T, et al.Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998;16(11):3502-3508.
28. Roche H, Fumoleau P, Spielmann M, et al. Five years analysis of PACS 01 trial: 6 cycles of FEC 100 vs 3 cycles of FEC 100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node-positive breast cancer. Breast Cancer Res Treat 2004;88:S16-S16.
29. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 1996;51(7):879-886.
30. Arbuck SG, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; (15):117-130.
31. Giordano SH, Booser DJ, Murray JL, et al. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and oneor three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002;8(11):3360-3368.
32. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999;17(11):3596-3602.
33. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002;105(13):1551-1554.
34. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009;10(4):391-399.
35. Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? J Am Coll Cardiol 2009;54(7):625-627.
36. Cho GY, Marwick TH, Kim HS, et al. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 2009;54(7):618-624.
37. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3(4):333-342.
38. Marwick TH, Raman SV, Carrio I, et al. Recent developments in heart failure imaging. JACC Cardiovasc Imaging 2010;3(4):429-439.
39. Jassal DS, Han SY, Hans C, et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009;22(4):418-424.
40. Sawaya H, Sebag I, Plana JC, et al. Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients: An Echocardiographic and Biomarker Study. American Society of Echocardiography 21st Annual Scientific Sessions; San Diego, California. 2010:AbstractP1-42.
41. [Internet] Reis L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. http://seer.cancer.gov/csr/1975_2004/
42. Ng AK, Travis LB. Subsequent malignant neoplasms in cancer survivors. Cancer J 2008;14(6):429-434.
43. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97(18):1354-1365.
44. Stava C, Beck M, Weiss LT, et al. Health profiles of 996 melanoma survivors: the M. D. Anderson experience. BMC Cancer 2006;6:95.
45. van der Gaast A, Postmus PE, Burghouts J, et al. Long term survival of small cell lung cancer patients after chemotherapy. Br J Cancer 1993;67(4):822-824.
46. Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer 2006;94(11):1745-1750.
47. Takigawa N, Kiura K, Segawa Y, et al. Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. Br J Cancer 2006;95(9):1142-1144.
48. Okines A, Thomson CS, Radstone CR, et al. Second primary malignancies after treatment for malignant lymphoma. Br J Cancer 2005;93(4):418-424.
49. Fernebro J, Bladstrom A, Rydholm A, et al. Increased risk of malignancies in a population-based study of 818 soft-tissue sarcoma patients. Br J Cancer 2006;95(8):986-990.
50. Kirova YM, De Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008;98(5):870-874.
51. Gianni L, Gelber S, Ravaioli A, et al. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer 2009;45(4):561-571.
52. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27(6):967-973.
53. Meadows AT, Friedman DL, Neglia JP, et al. Second Neoplasms in Survivors of Childhood Cancer: Findings From the Childhood Cancer Survivor Study Cohort. J Clin Oncol 2009; 27: 2356-2362.
54. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007;25(12):1489-1497.
55. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18(12):2435-2443.
56. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18(3):498-509.
57. Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100(6):1989-1996.
58. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21(23):4386-4394.
59. Heyne KH, Lippman SM, Lee JJ, et al. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol 1992;10(10):1519-1524.
60. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30(6):740-748.
61. Langeveld NE, Grootenhuis MA, Voute PA, et al. Quality of life, self-esteem and worries in young adult survivors of childhood cancer. Psychooncology 2004;13(12):867-881.
62. Hoffman KE, McCarthy EP, Recklitis CJ, et al. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 2009;169(14):1274-1281.
63. Zebrack BJ, Yi J, Petersen L, et al. The impact of cancer and quality of life for long-term survivors. Psychooncology 2008;17(9):891-900.
64. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
65. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005; 23: 5155-5165.
66. Carpenter KM, Andersen BL, Fowler JM, et al. Sexual self schema as a moderator of sexual and psychological outcomes for gynecologic cancer survivors. Arch Sex Rehab 2009; 38(5): 828-841.
67. Hickey M, Peate M, Saunders CM, et al. Breast cancer in young women and its impact on reproductive function. Human Reproduction Update; 2009; 15 (No 3): 323-339.
68. Sverrisdottir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004; 22: 3694-3699.
69. Bertero C. Altered sexual patterns after treatment for prostate cancer. Cancer Practice 2001; 9: 245-251.
70. Jenkins R, Schover LR, Fouladi RT, et al. Sexuality and health-related quality of life after prostate cancer in African-American and while men treated for localized disease. Journal of Sex & Marital Therapy 2004; 30: 79-93.
71. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 2792-2797.
72. Parker PA, Baile WF, De Moor C, et al. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psycho-Oncology 2003; 12: 183-193.
73. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist 2006; 11: 422-434.
74. Sabatino SA, Coates RJ, Uhler RJ, et al. Provider counseling about health behaviors among cancer survivors in the United States. J Clin Oncol 2007;25(15):2100-2106.
75. Hoffman B. Cancer survivors at work: a generation of progress. CA Cancer J Clin 2005;55(5):271-280.
76. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101(1):3-27.
77. de Boer AG, Taskila T, Ojajarvi A, et al. Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 2009;301(7):753-762.
78. Park ER, Li FP, Liu Y, et al. Health insurance coverage in survivors of childhood cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2005;23(36):9187-9197.